Researchers in Prof. Michael Lin's laboratory have developed a viral-based cancer therapy platform that could be used for targeting treatment to cancer cells with aberrant signaling in EGFR or HER2 pathways.
Researchers in Prof. Stephen Quake's laboratory have developed a CRISPER-Cas-based targeted endonuclease system designed to treat latent viral infections by attacking the viral genome.
Researchers in Prof. Mark Kay's laboratory have developed recombinant adeno-associated viral (AAV) capsid proteins that transduce human primary hepatocytes at high efficiency in vitro and in vivo.